Failure to Ensure Accurate and Continuous Administration of Critical Medications
Summary
The deficiency involves the facility’s failure to ensure residents were free from significant medication errors, particularly related to critical medications such as antirejection agents, anticonvulsants, and anticoagulants. One resident with a history of kidney and pancreatic transplants (R5) did not receive prescribed antirejection medications Mycophenolate Mofetil and Tacrolimus for extended periods. The MAR showed Mycophenolate Mofetil was not given or held for 37 days, and Tacrolimus was not given or held for several days. Progress notes documented that Mycophenolate Mofetil was not in the facility, required prior authorization, and was on hold per the nurse practitioner, with repeated entries that it was ordered but not available. For Tacrolimus, notes indicated it was ordered, held per the nurse practitioner, or ordered but not yet delivered. There was no medication error report found for the missed Tacrolimus doses. The pharmacy’s business assistant reported that the facility first requested refills for R5’s antirejection medications on a specific date and that the pharmacy repeatedly sent forms requesting transplant-related information and clarification on payment responsibility. The pharmacy documented multiple attempts over several days to obtain the needed information from the facility, with no response, leading the pharmacy to place the medication request on hold (“profiled”) until the facility reinitiated contact about a month later. The medications were eventually dispensed only after the DON agreed the facility would cover the cost pending insurance information. Interviews with the pharmacist and pharmacy staff emphasized that the facility commonly failed to respond in a timely manner to pharmacy requests. The DON later stated that staff should have notified the provider immediately about the interruption of antirejection medications, acknowledged awareness of the resident’s concern about not receiving these medications, and initially attributed the problem to the pharmacy not sending medications. The DON could not produce documentation showing that the requested pharmacy form had been completed prior to late March. R5 and a family member reported that the resident repeatedly asked the facility to refill antirejection medications and became anxious, afraid, and depressed when the medications were not provided for over a month. R5 stated that the transplant physician had instructed that antirejection medications were lifelong and should not be missed, and described daily feelings of anxiety, fear, and depression due to the prolonged lack of medication. The family member reported not being contacted for weeks and observed that the resident had become increasingly anxious, depressed, withdrawn, and preferred to stay in the room, feeling like a nuisance to staff. Facility staff, including the ADON, acknowledged that the resident and spouse were upset and concerned about transplant rejection and that the lack of antirejection medications could be contributing to the resident’s seclusion. Another resident (R3) with a history including end-stage renal disease, kidney transplant, and seizure prophylaxis was ordered Lacosamide 100 mg twice daily as an anticonvulsant. The MAR showed that Lacosamide was not given or held for four consecutive days. Progress notes documented that the medication was not available, ordered but not received, pending delivery, and that pharmacy had been called for a refill with an e-script request sent to the provider. The DON stated not knowing the resident was on an anticonvulsant and agreed the seizure medication should not have been missed, while also stating a belief that the missed doses did not contribute to the resident’s subsequent hospitalization. The nurse practitioner reported being unaware that the anticonvulsant had been missed for four days and stated that anticonvulsant medications should not be stopped abruptly. A third resident (R2) with chronic atrial fibrillation and other cardiac conditions was discharged from the hospital with instructions to take warfarin 2.5 mg orally once daily and to have repeat INR monitoring. The hospital discharge summary noted that the resident’s INR had been supratherapeutic on admission, warfarin had been held, and the INR had decreased prior to discharge, with specific follow-up INR dates recommended. At the facility, however, the medication orders documented that the resident was to receive warfarin 5 mg (two 2.5 mg tablets) on Mondays and Fridays and 2.5 mg on the remaining days, which did not match the hospital discharge instructions for a consistent 2.5 mg daily dose. A fourth resident (R9) experienced a warfarin dosing error when the facility failed to discontinue a previous warfarin order, resulting in the resident receiving a double dose. The report notes that R5’s case was cited at severity level 3 (actual harm) due to psychosocial harm manifested by ongoing anxiety, fear, and depression related to the prolonged lack of antirejection medications. The other residents’ cases (R2, R3, and R9) were cited at severity level 2 for potential for more than minimal harm. Across these examples, the facility did not follow its own medication ordering and receipt policy, did not ensure timely communication and follow-through with the pharmacy, did not consistently notify the provider of prolonged medication unavailability, and did not adhere to hospital discharge orders for warfarin dosing, resulting in significant medication errors and missed critical therapies.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release June 24, 2026) and official state health department websites — never guesswork.
Trusted by long-term care providers and associations.



